At a glance
- Current status: Open
- Fund type: SEIS/EIS
- Investment goal: Capital growth
- Focus: Deep Tech & Life Sciences
- Minimum portfolio size: 4 companies
- Target returns: 3x
- Target holding period: 8 years
- Minimum subscription: £10,000
"The MEDCAN Fund will target qualifying companies that exploit the therapeutic potential of the endocannabinoid system for use in global markets.” - Alexandre Ouimet-Storrs, Óskare Capital UK Ltd.
Óskare Capital UK Ltd has launched the first SEIS and/or EIS fund, investing in innovative companies and teams working on novel therapeutics utilising medical cannabis and other molecules that target an important signalling and regulatory system for maintaining health and fighting disease, the endocannabinoid system.
The MEDCAN Fund will target qualifying companies that exploit the therapeutic potential of the endocannabinoid system for use in global markets.
The Fund will invest in start-ups across the entire value chain (from molecule to patient) focusing on services and solutions surrounding the endocannabinoid system. It will not invest in growing or producing cannabis, nor will the Fund be involved in businesses or activities related to recreational cannabis.
SEIS & EIS tax incentives
The companies the fund invest in are expected to be SEIS-EIS-qualifying, which makes The MEDCAN Fund SEIS-EIS suitable for qualifying clients who would potentially benefit from the following tax reliefs:
- Up to 30% income tax relief (or 50% for SEIS)
- Tax-free investment growth
- Capital gains deferral (or 50% capital gains tax exemption for SEIS)
- Inheritance tax relief
- Loss relief
Please note: SEIS-EIS tax reliefs are only made available to investors because of the higher risks associated with investing in early-stage companies. Also, the availability of tax reliefs will depend on the investor's personal circumstances, and tax legislation can change in the future.
Examples of the fund team's previous investments
Octarine harnesses is synthetic biotechnology company with proprietary glycosylation and other functionalisation technologies (platform).
Herbolea develops novel biotech processing technologies to manufacture unique high quality products from high therapeutic potential botanicals such as cannabinoids and hops.
.svg)